US2002004482A1PendingUtilityA1

Treatment of acute lung injury and fibrosis with antagonists of avbeta6

30
Priority: Aug 8, 1997Filed: Aug 7, 1998Published: Jan 10, 2002
Est. expiryAug 8, 2017(expired)· nominal 20-yr term from priority
Inventors:Xiaozhu HuangDean SheppardRobert Pytela
A61P 35/04C07K 2317/76A61P 11/00A61P 13/12A61P 1/16C07K 14/70546C07K 16/2839A61K 38/39A01K 2217/05A61P 13/10A01K 2217/075A61K 38/16
30
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating acute lung injury in a patient comprising administering to the patient a therapeutic dose of an antagonist of αvβ6.  
     
     
         2 . The method of  claim 1  wherein the antagonist is an antibody which specifically binds to β6.  
     
     
         3 . The method of  claim 2  wherein the antibody is a monoclonal antibody.  
     
     
         4 . The method of  claim 1  wherein the antagonist comprises the amino acid sequence RGD.  
     
     
         5 . The method of  claim 1  wherein the antagonist comprises an antisense nucleic acid molecule.  
     
     
         6 . The method of  claim 1  wherein the antagonist is administered therapeutically.  
     
     
         7 . The method of  claim 1  wherein the antagonist is administered prophylactically.  
     
     
         8 . A method of treating fibrosis in a patient comprising administering to the patient a therapeutic dose of an antagonist of αvβ6.  
     
     
         9 . The method of  claim 8  wherein the fibrosis is pulmonary fibrosis.  
     
     
         10 . The method of  claim 9  herein the pulmonary fibrosis results from acute lung injury.  
     
     
         11 . The method of  claim 8  wherein the antagonist is an antibody which specifically binds to β6.  
     
     
         12 . The method of  claim 11  wherein the antibody is a monoclonal antibody.  
     
     
         13 . The method of  claim 8  wherein the antagonist comprises the amino acid sequence RGD.  
     
     
         14 . The method of  claim 8  wherein the antagonist comprises an antisense nucleic acid molecule.  
     
     
         15 . The method of  claim 8  wherein the antagonist is administered therapeutically.  
     
     
         16 . The method of  claim 8  wherein the antagonist is administered prophylactically.  
     
     
         17 . A monoclonal antibody produced by the hybridoma ATCC HB12382.  
     
     
         18 . The hybridoma ATCC HB12382.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.